HaloSource (HALO) Competitors

HaloSource logo
GBX 5.82 -0.06 (-1.00%)
As of 11/20/2026 12:33 PM Eastern

HALO vs. PXS, MXC, RGT, CEL, and IDP

Should you buy HaloSource stock or one of its competitors? HaloSource's main competitors and comparable companies include Provexis (PXS), Argent BioPharma (MXC), Argent BioPharma (RGT), Celadon Pharmaceuticals (CEL), and InnovaDerma (IDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does HaloSource compare to Provexis?

HaloSource (LON:HALO) and Provexis (LON:PXS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

HaloSource has higher earnings, but lower revenue than Provexis. Provexis is trading at a lower price-to-earnings ratio than HaloSource, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HaloSourceN/AN/AN/A-£3.72N/A
Provexis£1.26M12.89-£619.15K-£0.02N/A

In the previous week, HaloSource's average media sentiment score of 0.00 equaled Provexis'average media sentiment score.

Company Overall Sentiment
HaloSource Neutral
Provexis Neutral

7.9% of Provexis shares are held by institutional investors. 11.8% of Provexis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

HaloSource has a net margin of 0.00% compared to Provexis' net margin of -39.76%. HaloSource's return on equity of 0.00% beat Provexis' return on equity.

Company Net Margins Return on Equity Return on Assets
HaloSourceN/A N/A N/A
Provexis -39.76%-44.68%-56.14%

Summary

HaloSource and Provexis tied by winning 4 of the 8 factors compared between the two stocks.

How does HaloSource compare to Argent BioPharma?

Argent BioPharma (LON:MXC) and HaloSource (LON:HALO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

1.2% of Argent BioPharma shares are owned by institutional investors. 8.2% of Argent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Argent BioPharma's average media sentiment score of 0.00 equaled HaloSource'saverage media sentiment score.

Company Overall Sentiment
Argent BioPharma Neutral
HaloSource Neutral

Company Net Margins Return on Equity Return on Assets
Argent BioPharmaN/A N/A -58.96%
HaloSource N/A N/A N/A

HaloSource has lower revenue, but higher earnings than Argent BioPharma. HaloSource is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Argent BioPharma£1.32M0.00-£17.02M-£1.66N/A
HaloSourceN/AN/AN/A-£3.72N/A

Summary

Argent BioPharma beats HaloSource on 4 of the 6 factors compared between the two stocks.

How does HaloSource compare to Argent BioPharma?

Argent BioPharma (LON:RGT) and HaloSource (LON:HALO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

1.1% of Argent BioPharma shares are held by institutional investors. 17.8% of Argent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Argent BioPharma's average media sentiment score of 0.00 equaled HaloSource'saverage media sentiment score.

Company Overall Sentiment
Argent BioPharma Neutral
HaloSource Neutral

HaloSource has a net margin of 0.00% compared to Argent BioPharma's net margin of -1,967.38%. Argent BioPharma's return on equity of 279.26% beat HaloSource's return on equity.

Company Net Margins Return on Equity Return on Assets
Argent BioPharma-1,967.38% 279.26% -108.57%
HaloSource N/A N/A N/A

HaloSource is trading at a lower price-to-earnings ratio than Argent BioPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Argent BioPharmaN/AN/A-£17.53M-£0.24N/A
HaloSourceN/AN/AN/A-£3.72N/A

Summary

Argent BioPharma beats HaloSource on 5 of the 7 factors compared between the two stocks.

How does HaloSource compare to Celadon Pharmaceuticals?

Celadon Pharmaceuticals (LON:CEL) and HaloSource (LON:HALO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

10.7% of Celadon Pharmaceuticals shares are held by institutional investors. 65.1% of Celadon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Celadon Pharmaceuticals' average media sentiment score of 0.00 equaled HaloSource'saverage media sentiment score.

Company Overall Sentiment
Celadon Pharmaceuticals Neutral
HaloSource Neutral

HaloSource has lower revenue, but higher earnings than Celadon Pharmaceuticals. Celadon Pharmaceuticals is trading at a lower price-to-earnings ratio than HaloSource, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celadon Pharmaceuticals£123.38K66.61-£4.97M-£7.98N/A
HaloSourceN/AN/AN/A-£3.72N/A

HaloSource has a net margin of 0.00% compared to Celadon Pharmaceuticals' net margin of -9,520.00%. HaloSource's return on equity of 0.00% beat Celadon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Celadon Pharmaceuticals-9,520.00% -131.82% -34.40%
HaloSource N/A N/A N/A

Summary

HaloSource beats Celadon Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

How does HaloSource compare to InnovaDerma?

HaloSource (LON:HALO) and InnovaDerma (LON:IDP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

Company Net Margins Return on Equity Return on Assets
HaloSourceN/A N/A N/A
InnovaDerma N/A N/A N/A

HaloSource is trading at a lower price-to-earnings ratio than InnovaDerma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HaloSourceN/AN/AN/A-£3.72N/A
InnovaDerma£9.82M0.00N/A-£7.50N/A

In the previous week, HaloSource's average media sentiment score of 0.00 equaled InnovaDerma'saverage media sentiment score.

Company Overall Sentiment
HaloSource Neutral
InnovaDerma Neutral

Summary

HaloSource beats InnovaDerma on 2 of the 3 factors compared between the two stocks.

Get HaloSource News Delivered to You Automatically

Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HALO vs. The Competition

MetricHaloSourcePharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£6.44M£13.62B£7.78B£2.67B
Dividend YieldN/A2.58%2.47%5.11%
P/E Ratio-1.5627.5233.2222.78
Price / SalesN/A6.788.104.91
Price / CashN/A15.6321.0120.23
Price / BookN/A5.164.262.40
Net IncomeN/A£2.86B£3.50B£5.88B
1 Month Performance-26.15%-9.80%-10.48%-4.75%
1 Year PerformanceN/A-8.93%-4.61%5.15%

HaloSource Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HALO
HaloSource
N/AGBX 5.82
-1.0%
N/AN/A£6.44MN/AN/A390
PXS
Provexis
N/AGBX 0.90
+11.8%
N/A+15.8%£21.11M£1.26MN/A4
MXC
Argent BioPharma
N/AN/AN/AN/A£9.65M£1.32MN/A5
RGT
Argent BioPharma
N/AN/AN/AN/A£8.31MN/AN/AN/A
CEL
Celadon Pharmaceuticals
N/AGBX 13.40
flat
N/AN/A£8.22M£123.38KN/A2,780

Related Companies and Tools


This page (LON:HALO) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners